Noema Pharma Secures CHF 130 Million with EQT Life Sciences' Series B Extension

The clinical-stage biotech company Noema Pharma has successfully extended its Series B funding round, raising a total of CHF 130 million in a bid to advance its clinical pipeline targeting central nervous system (CNS) disorders. This extension was led by EQT Life Sciences, part of the EQT platform, with participation from a consortium of global biotechnology investors. The capital infusion aims to support late-stage clinical trial readouts anticipated in 2025 for multiple treatments addressing severe neurological diseases, a field characterized by high unmet medical needs. The company's therapeutic portfolio includes innovative treatments in Phase 2 trials for conditions such as trigeminal neuralgia, tuberous sclerosis complex, Tourette syndrome, and CNS-mediated symptoms of menopause. EQT Life Sciences' partnership with Noema Pharma reflects a strategic alignment towards pioneering treatments for CNS disorders, driven by the leadership of Noema Pharma's CEO, Ilise Lombardo, MD, and guided by EQT's strategic investments in groundbreaking healthcare solutions. The involvement of Felice Verduyn-van Weegen, Partner at EQT, as a board member of Noema Pharma further emphasizes the importance of this collaboration. Noema Pharma, with its headquarters in Basel, Switzerland, continues its mission to leverage its innovative assets to transform outcomes for patients suffering from these challenging CNS disorders.